公开(公告)号：US20240108656A1

公开(公告)日：2024-04-04

申请号：US18539876

申请日：2023-12-14

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Lan Cao ,  Hui-Hsin Chang ,  Jianxin Hu ,  Yu Qian ,  Xi Shi

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K14/54 ,  C07K16/28 ,  C12N5/00 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464411 ,  A61K39/46444 ,  A61P35/02 ,  C07K14/5443 ,  C07K16/2803 ,  C12N5/0018 ,  C12N5/0646 ,  A61K2239/13 ,  A61K2239/28 ,  A61K2239/48

摘要： The present disclosure provides, among other things, a method for efficiently producing a cell population enriched in Natural Killer cells (NK cells) from induced pluripotent cells.

公开(公告)号：US20240108651A1

公开(公告)日：2024-04-04

申请号：US18255633

申请日：2021-12-02

申请人： Thomas Jefferson University

发明人： Adam Eugene Snook ,  My Georgia Mahoney ,  Robert Devlin Carlson

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464402 ,  A61P35/00 ,  C07K16/28 ,  A61K2239/13

摘要： The present disclosure relates to Dsg2 binding molecules, nucleic acid molecules encoding the Dsg2 binding molecules and compositions comprising the same and methods of use thereof for treating or preventing cancer.

公开(公告)号：US20240082302A1

公开(公告)日：2024-03-14

申请号：US17767831

申请日：2020-10-09

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Xianxin HUA ,  Xin HE ,  Xuyao ZHANG

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K16/28 ,  C07K16/40

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61K39/464454 ,  A61P35/02 ,  C07K16/2803 ,  C07K16/40 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/29 ,  A61K2239/48

摘要： The present invention includes compositions and methods for treating AML utilizing bispecific CARs. In certain aspects, the invention includes a bispecific split CAR which binds CD13 and TIM-3 on AML cells. In one aspect, the invention provides a bispecific chimeric antigen receptor (CAR) comprising a first antigen binding domain capable of binding CD13, a first intracellular domain, a second antigen binding domain capable of binding TIM-3, a transmembrane domain, and a second intracellular domain.

公开(公告)号：US20240075065A1

公开(公告)日：2024-03-07

申请号：US18321344

申请日：2023-05-22

申请人： LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN

发明人： Tobias FEUCHTINGER ,  Semjon WILLIER

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/02 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61K45/06 ,  A61P35/02 ,  C07K16/2818 ,  C12N5/0636 ,  C12N15/86 ,  A61K2239/13 ,  A61K2239/21

摘要： The present invention relates to a modified T cell, comprising (a) a disrupted endogenous CD28-encoding gene; and (b) a polynucleotide encoding a chimeric antigen receptor (CAR), wherein the CAR comprises in its ectodomain at least one antigen binding moiety that is capable of specific binding to the extracellular portion of CD28. The invention furthermore relates to a population of the modified T cells, to a method for generating modified T cells and medical and non-medical uses thereof.

公开(公告)号：US20240067706A1

公开(公告)日：2024-02-29

申请号：US18270917

申请日：2022-01-05

申请人： CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES

发明人： Bing Sun ,  Xiaoyu Sun ,  Chunyan Yi ,  Zhiyang Ling ,  Yaguang Zhang

IPC分类号： C07K16/10 ,  A61K39/00 ,  A61P31/14 ,  C12N5/0783 ,  G01N33/569

CPC分类号： C07K16/1003 ,  A61K39/4611 ,  A61K39/4631 ,  A61P31/14 ,  C12N5/0636 ,  G01N33/56983 ,  A61K2239/13 ,  A61K2239/38 ,  C07K2317/565 ,  C07K2317/622 ,  C12N2510/00

摘要： Disclosed are a fully human broad-spectrum neutralizing antibody against coronavirus, and the use thereof. Specifically disclosed are a fully human monoclonal antibody against an S2 region of coronavirus S protein, a nucleic acid sequence encoding the antibody, and a preparation method therefor. The antibody can effectively bind to and neutralize a variety of coronaviruses in a broad spectrum manner, and can be used for preventing and treating diseases related to coronavirus infection, such as SARS-CoV-2. Further disclosed is the potential use thereof in vaccine design.

公开(公告)号：US20240052055A1

公开(公告)日：2024-02-15

申请号：US18266393

申请日：2021-12-09

申请人： Simcere Zaiming Pharmaceutical Co., Ltd.

发明人： Shumei You ,  Cuiqing Yang ,  Zhuoxiao Cao ,  Renhong Tang ,  Jinsheng Ren

IPC分类号： C07K16/30 ,  A61K39/00 ,  G01N33/574

CPC分类号： C07K16/303 ,  A61K39/464474 ,  G01N33/57492 ,  A61K39/4631 ,  C07K2317/92 ,  C07K2317/33 ,  C07K2317/31 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2317/24 ,  A61K2239/13

摘要： Provided are a GPC3 antibody and an application thereof, and specifically provided are an antibody or an antigen-binding fragment that specifically binds to GPC3, a multispecific antigen-binding molecule, a chimeric antigen receptor, an immune effector cell, isolated nucleic acid fragments, a vector, a host cell, a corresponding preparation method, a pharmaceutical composition, a treatment method, a pharmaceutical use, a GPC3 detection method and a detection kit. The present disclosure is of great significance in the preparation of drugs for treating cancer or tumor.

公开(公告)号：US20240033356A1

公开(公告)日：2024-02-01

申请号：US18037676

申请日：2021-11-18

申请人： CARINA BIOTECH PTY LTD

发明人： Justin Taylor COOMBS ,  Shaun Reuss MCCOLL ,  Simon Charles BARRY

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61P35/00

CPC分类号： A61K39/4631 ,  A61K35/17 ,  A61K39/464402 ,  A61P35/00 ,  A61K2239/21 ,  A61K2239/13

摘要： N(57) Abstract: There is a need for new and alternative options for immune therapy of proliferative diseases such as cancer. This need C\11 may be address by providing a chimeric antigen receptor having an extracellular domain including a binding domain which recognises Nthe cancer-stem-cell-associated protein Lgr5; a transmembrane domain; and an intracellular signalling domain that activates a cellular .,, function. Such CAR T cells can be used to kill cancer cells and treat or prevent cancer in a subject.

公开(公告)号：US20240024476A1

公开(公告)日：2024-01-25

申请号：US18260376

申请日：2022-01-06

申请人： Innovative Cellular Therapeutics Holdings, Ltd. ,  Innovative Cellular Therapeutics, Inc.

发明人： Chengfei Pu ,  Zhiyuan Cao ,  Xiaogang Shen ,  Wensheng Wang ,  Beibei Jia ,  Dongqi Chen ,  Xiaoqiang Xu ,  Xudong Tang ,  Wei Ding ,  Xianyang Jiang ,  Yuzhe Peng ,  Guiting Han ,  Le Tian ,  Zhao Wu ,  Lei Xiao

IPC分类号： A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C07K16/30 ,  C07K16/28 ,  C07K16/18 ,  C07K16/40 ,  A61P35/00

CPC分类号： A61K39/4631 ,  C07K14/7051 ,  C12N5/0636 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/2875 ,  C07K16/2803 ,  C07K16/28 ,  C07K16/2851 ,  C07K16/18 ,  C07K16/40 ,  A61P35/00 ,  A61K39/4611 ,  A61K39/4644 ,  A61K39/464474 ,  A61K39/464417 ,  A61K39/464402 ,  A61K39/464458 ,  A61K39/464411 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2317/622 ,  A61K2239/13 ,  C07K2317/31

摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.

公开(公告)号：US20240016841A1

公开(公告)日：2024-01-18

申请号：US18251992

申请日：2021-11-05

申请人： Triumvira Immunologics USA, Inc. ,  McMaster University

发明人： Jonathan Lorne Bramson ,  SeungMi Yoo ,  Sarah Asbury ,  Allyson Moore ,  Ling Wang ,  Brian Philip

IPC分类号： A61K35/17 ,  A61K31/675 ,  C07K16/28 ,  C07K16/32 ,  A61K39/00 ,  A61K38/20 ,  A61P35/00

CPC分类号： A61K35/17 ,  A61K31/675 ,  C07K16/2803 ,  C07K16/32 ,  C07K16/2878 ,  A61K39/4611 ,  A61K39/464406 ,  A61K39/464412 ,  A61K38/2013 ,  A61P35/00 ,  A61K2239/13 ,  A61K2239/21

摘要： γδ T cells comprising a molecule comprising (i) a target-specific antigen-binding domain, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.

公开(公告)号：US20240009309A1

公开(公告)日：2024-01-11

申请号：US18347487

申请日：2023-07-05

申请人： Neomics Pharmaceuticals LLC

发明人： William A. COMRIE ,  Wenshan HAO

IPC分类号： A61K39/00 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  A61P35/00

CPC分类号： A61K39/464417 ,  C07K16/2878 ,  C07K14/7051 ,  A61K39/4631 ,  C07K14/70521 ,  A61P35/00 ,  A61K39/4611 ,  A61K2239/22 ,  C07K2317/569 ,  A61K2239/48 ,  A61K2239/13 ,  C07K2319/33

摘要： The present application relates to functionally improved third generation BCMA-CARs comprising modified intracellular co-stimulatory domains, which can be used in adoptive cell therapy, e.g., in treatment of diseases and disorders such as cancer.